Infectious events in patients with alopecia areata treated with JAK inhibitors: low burden and minimal impact on persistence in treatment.

IF 3 3区医学 Q2 PHARMACOLOGY & PHARMACY

Expert Opinion on Drug Safety Pub Date : 2024-11-01 Epub Date: 2024-05-08 DOI:10.1080/14740338.2024.2348571

Giacomo Caldarola, Lorenzo Maria Pinto, Francesco Bellinato, Nicoletta Bernardini, Elena Campione, Andrea Chiricozzi, Laura Colonna, Clara De Simone, Laura Diluvio, Paolo Gisondi, Enrico Matteini, Eleonora Tomassetti, Ersilia Tolino, Luca Bianchi, Ketty Peris

{"title":"Infectious events in patients with alopecia areata treated with JAK inhibitors: low burden and minimal impact on persistence in treatment.","authors":"Giacomo Caldarola, Lorenzo Maria Pinto, Francesco Bellinato, Nicoletta Bernardini, Elena Campione, Andrea Chiricozzi, Laura Colonna, Clara De Simone, Laura Diluvio, Paolo Gisondi, Enrico Matteini, Eleonora Tomassetti, Ersilia Tolino, Luca Bianchi, Ketty Peris","doi":"10.1080/14740338.2024.2348571","DOIUrl":null,"url":null,"abstract":"Background: Alopecia areata (AA) is a non-scarring disorder characterized by hair loss that greatly affects patients' quality of life and has a chronic, recurring course. This disease is marked by an inflammatory process, mainly on an autoimmune basis primarily regulated by Janus kinase (JAK).Research design and methods: We conducted a retrospective study evaluating the safety of JAKi in a real-world setting in 91 AA patients, with a specific focus on the assessment of infectious events.Results: Overall, 34 infectious events were observed in 28 patients (30.8%), among them 17 patients (60.7%) suspended treatment with JAKi until the infection was clinically resolved. Only in one case the infectious event led to a permanent discontinuation of the treatment. The data we observed in the study are consistent with results reported in clinical trials.Conclusion: It can be stated that, during treatment with JAKi in AA patients, infectious events may occur, but in most cases these events are easily manageable and do not result in permanent discontinuation of the drug.","PeriodicalId":12232,"journal":{"name":"Expert Opinion on Drug Safety","volume":" ","pages":"1483-1487"},"PeriodicalIF":3.0000,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Opinion on Drug Safety","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/14740338.2024.2348571","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/5/8 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Alopecia areata (AA) is a non-scarring disorder characterized by hair loss that greatly affects patients' quality of life and has a chronic, recurring course. This disease is marked by an inflammatory process, mainly on an autoimmune basis primarily regulated by Janus kinase (JAK).

Research design and methods: We conducted a retrospective study evaluating the safety of JAKi in a real-world setting in 91 AA patients, with a specific focus on the assessment of infectious events.

Results: Overall, 34 infectious events were observed in 28 patients (30.8%), among them 17 patients (60.7%) suspended treatment with JAKi until the infection was clinically resolved. Only in one case the infectious event led to a permanent discontinuation of the treatment. The data we observed in the study are consistent with results reported in clinical trials.

Conclusion: It can be stated that, during treatment with JAKi in AA patients, infectious events may occur, but in most cases these events are easily manageable and do not result in permanent discontinuation of the drug.

查看原文本刊更多论文

接受 JAK 抑制剂治疗的斑秃患者中的感染事件：负担较轻，对持续治疗的影响很小。

背景：斑秃（AA）是一种以脱发为特征的非瘢痕性疾病，严重影响患者的生活质量，病程慢性，反复发作。这种疾病以炎症过程为特征，主要是受 Janus 激酶（JAK）调控的自身免疫性过程：我们进行了一项回顾性研究，评估了 JAKi 在真实世界环境中对 91 名 AA 患者的安全性，重点评估了感染事件：28名患者（30.8%）共发生了34起感染事件，其中17名患者（60.7%）暂停了JAKi治疗，直到感染得到临床缓解。只有一例患者因感染事件而永久停止了治疗。我们在研究中观察到的数据与临床试验报告的结果一致：可以说，AA患者在使用JAKi治疗期间可能会发生感染事件，但在大多数情况下，这些事件很容易控制，不会导致永久停药。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Expert Opinion on Drug Safety 医学-药学

CiteScore

5.90

自引率

3.20%

发文量

审稿时长

6-12 weeks

期刊介绍： Expert Opinion on Drug Safety ranks #62 of 216 in the Pharmacology & Pharmacy category in the 2008 ISI Journal Citation Reports. Expert Opinion on Drug Safety (ISSN 1474-0338 [print], 1744-764X [electronic]) is a MEDLINE-indexed, peer-reviewed, international journal publishing review articles on all aspects of drug safety and original papers on the clinical implications of drug treatment safety issues, providing expert opinion on the scope for future development.